The changes and challenges wrought by COVID-19 have significantly impacted the medtech industry—through product portfolios, work habits, and processes. Only time will tell what practices will become permanent after the pandemic, but surely a new cast of players, changing work practices, and heightened regulatory urgency are not likely to disappear with the virus. Many outside companies that helped the healthcare industry battle the coronavirus through FDA emergency use authorizations (EUAs) are planning to remain in the medical device industry once the pandemic ends. Existing medtech organizations, meanwhile, are evaluating opportunities in new therapy areas. Click Here For Complete Article Text
|
|||||||||||||||||||||||||||
| Application Sequencing | |||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
| Company | Product | Process | Other Subjects | Event | Event Date | Location | Publication | Publication Date | Text Descriptor | ||||||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||||||||